Phase II study of PX-866 in recurrent glioblastoma

Neuro-Oncology

Volumn 17, Issue 9, 2015, Pages 1270-1274

  Pitz, Marshall W ^a   Eisenhauer, Elizabeth A ^b   MacNeil, Mary V ^c   Thiessen, Brian ^d   Easaw, Jacob C ^e   Macdonald, David R ^f   Eisenstat, David D ^g   Kakumanu, Ankineedu S ^h   Salim, Muhammad ^h   Chalchal, Haji ^h   Squire, Jeremy ^b   Tsao, Ming Sound ⁱ   Kamel Reid, Suzanne ⁱ   Banerji, Shantanu ^a   Tu, Dongsheng ^b   Powers, Jean ^b   Hausman, Diana F ^j   Mason, Warren P ^k  

^a CANCERCARE MANITOBA   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e TOM BAKER CANCER CENTRE   (Canada)

^f LONDON REGIONAL CANCER PROGRAM   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h Allan Blair Cancer Centre   (Canada)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

^j University of Toronto ^*  (United States)

^k UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

clinical trial; glioblastoma; PI3K

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATROPINE; BILIRUBIN; CREATININE; DIPHENOXYLATE; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; GROWTH FACTOR RECEPTOR; LOPERAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN; PIK3R1 PROTEIN; SONOLISIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GONANE DERIVATIVE; PX-866;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EXAMINATION; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; LEUKOPENIA; LIVER TOXICITY; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MUTATION; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; VOMITING; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; CLINICAL TRIAL; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; GONANES; HUMANS; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; TREATMENT OUTCOME;

EID: 84940778136     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou365     Document Type: Article

References (31)

1. Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol. 2006;8(1):27-37.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
3. Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010;28(12):2051-2057.
4. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. 2013;v.1.2013. www.nccn.org.
6. Mason WP, Maestro RD, Eisenstat D, et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol. 2007;14(3):110-117.
7. Eisenstat D. Complex chemotherapy for recurrent glioblastoma multiforme in adults. MIMS Advances. 2005;0:9-14.
8. Olson JJ, Nayak L, Ormond DR, et al. The role of targeted therapies in the management of progressive glioblastoma. J Neurooncol. 2014;118(3):557-599.
9. Ihle NT, Williams R, Chow S, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther. 2004;3(7): 763-772.
10. Chalhoub N, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009;4:127-150.
11. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550-562.
12. Ihle NT, Lemos R Jr., Wipf P, et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009;69(1):143-150.
13. Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8): 627-644.
14. Maira S, Stauffer F, Schnell C. PI3 K inhibitors for cancer treatment: where do we stand? Biochem Soc Trans. 2009;37:265-272.
15. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
16. Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol. 2009;27(34):5743-5750.
17. Courtney KD, Corcoran RB, Engelman JA. The PI3 K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6): 1075-1083.
18. Choe G, Horvath S, Cloughesy TF, et al. Analysis of the phosphatidylinositol 3-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003;63(11):2742-2746.
19. Li B, Yuan M, Kim I, et al. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene. 2004;23(26):4594-4602.
20. Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Epidermal growth factor ligand-independent, unregulated, celltransforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 1995;6(10):1251-1259.
21. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93(16):1246-1256.
22. Ermoian RP, Furniss CS, Lamborn KR, et al. Dysregulation of PTEN and protein kinase B Is associated with glioma histology and patient survival. Clin Cancer Res. 2002;8(5):1100-1106.
23. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
24. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670): 554.
25. Mizoguchi M, Nutt C, Mohapatra G, et al. Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathol. 2004;14(4):372-377.
26. Koul D, Shen R, Kim Y. Cellular and in vivo activity of a novel PI3 K inhibitor, PX-866, against human glioblastoma. Neuro Oncol. 2010;12(6):559-569.
27. Bowles DW, Ma WW, Senzer N, et al. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer. 2013;109(5):1085-1092.
28. Hong DS, Bowles DW, Falchook GS, et al. A multicenter phase 1 trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012;18(15):4173-4182.
29. Macdonald DR, Cascino TL, Schold SC Jr., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
30. Zee B, Melnychuk D, Dancey J, et al. Multinomial phase II cancer trials incorporating response and early progression. J Biopharm Stats. 1999;9(2):351-363.
31. Cloughesy TF, Cavenee WK, Mischel PS. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol. 2014;9:1-25.